Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. develops sublingual delivery technology designed to deliver drugs and other bioactive substances through rapid absorption under the tongue. Company news commonly covers its drug-delivery platform, applications across active pharmaceutical ingredients, therapeutics, nutraceuticals and supplements, and clinical or regulatory disclosures tied to its development activities.
Updates also include the company’s wholly owned Buzz Bomb Caffeine Company, which markets BUZZ BOMB™ caffeine in single-serving dry powder stick packs for sublingual use. Recurring corporate developments include retail distribution and sales agreements, operating and financial results, shareholder voting matters, governance updates, Nasdaq listing compliance and capital-structure actions such as reverse stock split approvals.
Aspire Biopharma (NASDAQ:ASBP) subsidiary Buzz Bomb Caffeine Company announced that elite ultramarathoner Ashley Paulson will attempt the female world record for the fastest 100-mile treadmill run at the Boston Marathon Expo on April 18, 2026 at the Hynes Convention Center.
Paulson previously set the 100-mile road world record on February 20, 2026 with a time of 12:19:34 and will aim to beat the treadmill mark of 14:15:08. The event will be live and open to spectators, showcasing Buzz Bomb products.
Aspire Biopharma (NASDAQ:ASBP) signed a Letter of Intent on April 16, 2026 to acquire Dura Driver Control Systems (DCS), a global automotive supplier with 100+ year leadership experience. The proposed acquisition would be for $30 million cash, subject to due diligence and a U.S. GAAP audit.
DCS reported $200M+ revenue and $20M+ adjusted EBITDA for FY2025 (unaudited), holds 310 patents across 275 parts, and serves 150+ vehicle platforms. Management additions from Lakewood & Company add collective industry expertise.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company has signed a sales and marketing brokerage agreement with Interwest Brokerage to expand BUZZ BOMB™ retail distribution across Utah, Idaho, and Montana.
The partnership assigns Interwest to lead sales, marketing, and distribution in grocery, convenience, and alternate channels to increase shelf presence and product velocity.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company entered an agreement with TruLife Distribution on March 19, 2026, to manage national sales, distribution, and merchandising of BUZZ BOMB™.
The partnership targets natural, organic, specialty, and mass-merchandiser channels to expand retail footprint for the single‑serve 50mg dry‑powder caffeine stick packs.
Aspire Biopharma (Nasdaq:ASBP) announced on March 17, 2026 that subsidiary Buzz Bomb Caffeine Company appointed John Choe as Western Sales Director. Choe is described as a 25-year industry veteran with prior roles at Yerbaé (2016–2025) and a reported 70% sales increase.
The announcement highlights Choe's experience in retail and beverage distribution, DSD and wholesale relationships, multilingual skills, and his MBA and BS degrees as assets to scale Buzz Bomb's western U.S. sales efforts.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company will feature its flagship product BUZZ BOMB™ at The Health & Fitness Show, March 16-18, 2026 in San Diego.
BUZZ BOMB™ is a 50mg single-serving dry powder stick pack designed to be sprinkled under the tongue for rapid caffeine absorption, portable dosing, and natural flavors with organic, non-GMO caffeine.
Aspire Biopharma (Nasdaq: ASBP) subsidiary Buzz Bomb Caffeine Company is launching a new BUZZ BOMB Convenience Store Pack, a six-count "Fruit Blast" offering with two each of Tropical Fruit, Mixed Berry, and Peach Mango.
Each single-serving stick contains 50mg fast-acting dry powder caffeine delivered under the tongue; rollout begins in select convenience stores starting in May.
Aspire Biopharma (Nasdaq:ASBP) announced a strategic partnership with Microsize to develop a patent-pending, rapid-delivery sublingual alprazolam powder intended to bypass the digestive tract for faster anxiety relief.
Aspire plans a Phase 1 clinical trial in mid-2026, engaged Pace for formulation and stability work, and cites >15.8 million U.S. prescriptions in 2023 and a projected global alprazolam powder market of $55.84 billion by 2032.
Aspire Biopharma (Nasdaq:ASBP) reported a major brand boost for its wholly owned Buzz Bomb Caffeine Company after sponsoring elite runner Ashley Paulson at the 2026 Jackpot Ultra Running Festival.
Key points: Buzz Bomb content surpassed 400,000 views in 48 hours, and Paulson set a new women's 100-mile world record of 12:19:34, with the company citing increased online revenue and consumer acquisition.
Aspire Biopharma (NASDAQ:ASBP) regained full compliance with Nasdaq continued listing requirements on February 20, 2026.
The company met the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and earlier met the $1.00 minimum bid requirement under Rule 5550(a)(2). Nasdaq confirmed the matter is closed, but Aspire will remain under a Panel Monitor through February 18, 2027.